Tianjin Saixiang Technology Co., Ltd. Class A 002337

SZSE · China · Producer Manufacturing

CNY 4.73-0.04 (-0.84%)

Market closed· Sep 30, 2026, 7:04 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Tianjin Saixiang Technology Co., Ltd. Class A 002337

SZSE · China · Producer Manufacturing

CNY 4.73-0.04 (-0.84%)

Market closed· Sep 30, 2026, 7:04 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-22.84% · 6MFull-screen chart

Open CNY 4.78High CNY 4.79Low CNY 4.71Close CNY 4.73Volume 6.51M

Sep 30, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: CNY 4.77
Day range: CNY 4.71 – CNY 4.79
52-week range: CNY 4.03 – CNY 8.21
Volume: 6.51M
Market cap: CNY 2.75B
P/E (TTM): 94.6
Dividend yield (annualized): 0.55%
Avg. volume (1Y): 15.75M

Performance

1 week

-2.87%

1 month

-1.05%

3 months

+4.19%

6 months

-19.28%

Year to date

-26.74%

1 year

-19.56%

Total return, dividends included.

Company profile

Sector: Producer Manufacturing
Industry: Industrial Machinery
Country: China
Exchange: SZSE
Shares outstanding: 584.33M
Employees: 874
ISIN: CNE100000K98
Beta: 1.15

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceAug 10, 2026

Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally

Baird Medical and Alpmed Le (Lynn) Zhang, Vice President of Baird Medical Group, and Jiliang (William) Zhang, Vice President of Alpmed, at the signing of the companies’ strategic partnership agreement Agreement combines Baird Medical's clinical, regulatory, and global commercialization expertise with Alpmed's leadership in IRE technologyCollaboration will advance technology development, global regulatory approvals, commercialization, and clinical adoption across key international markets, includ

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.